Advertisement: China mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: Cambridge Network
RealVNC mid banner careers
Mid banner advertisement: BDO
Advertisement: EY Mid banner
RealVNC mid-banner general
Barr Ellison Solicitors – commercial property
Advertisement: RSM
Advertisement: Simpsons Creative
Advertisement: EBCam mid banner
Advertisement: Mogrify mid banner
ARM Innovation Hub
1 September, 2020 - 10:53 By Tony Quested

Cambridge Cognition wins £2m deal for key schizophrenia trials

Cambridge Cognition, which develops and markets digital solutions to assess brain health, has won a £2 million contract as the cognitive assessment partner for three late phase clinical trials for a pharmaceutical company's lead drug candidate for patients with schizophrenia.

It is one of the largest single contracts secured by the business – quoted on AIM in the UK – and the revenue should be booked over the next four years with the majority recognised in 2021.

Schizophrenia is a psychotic disorder that affects more than 20 million people worldwide.  With new avenues of research being explored in recent years, more drugs have been launched (an increase of 30 per cent in five years) and there is increasing interest in drug development in the field.

Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Given the importance of this disorder, schizophrenia has been a core area of clinical focus for the company for the last three years as CANTAB cognitive assessments have a high degree of sensitivity in measuring these distinct processes. 

The fact that a pharmaceutical company has now chosen Cambridge Cognition as the cognitive assessment provider for three late stage trials recognises the investment that has been made in this field by the team. 

The pharmaceutical company involved will conduct two five-week inpatient trials of efficacy and safety of the drug as well as a 52-week open-label extension study. 

Cambridge Cognition will support all three trials with what the company believes to be gold-standard computerised cognitive assessment software, CANTAB, together with associated clinical trial services.

CEO Matthew Stork said: “We are delighted to have won this contract, which is considerably larger than our typical contract size, to support this large trial and work with a company that recognises the importance of sensitive and accurate cognitive assessment in schizophrenia. It is an outstanding endorsement for CANTAB in this growing area research.”

Newsletter Subscription

Stay informed of the latest news and features